Eli Lilly And Co (LLY) Shares Bought by River & Mercantile Asset Management LLP

River & Mercantile Asset Management LLP raised its stake in Eli Lilly And Co (NYSE:LLY) by 22.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 98,213 shares of the company’s stock after purchasing an additional 17,910 shares during the period. Eli Lilly And Co accounts for about 1.0% of River & Mercantile Asset Management LLP’s holdings, making the stock its 18th biggest position. River & Mercantile Asset Management LLP’s holdings in Eli Lilly And Co were worth $11,366,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently made changes to their positions in LLY. Vanguard Group Inc. lifted its holdings in Eli Lilly And Co by 0.7% in the third quarter. Vanguard Group Inc. now owns 74,132,985 shares of the company’s stock valued at $7,955,211,000 after acquiring an additional 511,752 shares during the period. Vanguard Group Inc increased its position in shares of Eli Lilly And Co by 0.7% in the third quarter. Vanguard Group Inc now owns 74,132,985 shares of the company’s stock valued at $7,955,211,000 after buying an additional 511,752 shares in the last quarter. BlackRock Inc. increased its position in shares of Eli Lilly And Co by 3.0% in the fourth quarter. BlackRock Inc. now owns 68,956,519 shares of the company’s stock valued at $7,979,649,000 after buying an additional 2,030,845 shares in the last quarter. Oregon Public Employees Retirement Fund increased its position in shares of Eli Lilly And Co by 17,720.8% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 42,420,406 shares of the company’s stock valued at $367,000 after buying an additional 42,182,367 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Eli Lilly And Co by 6.8% in the fourth quarter. Geode Capital Management LLC now owns 13,108,002 shares of the company’s stock valued at $1,514,582,000 after buying an additional 830,689 shares in the last quarter. Institutional investors own 79.58% of the company’s stock.

A number of research analysts have recently weighed in on LLY shares. Cantor Fitzgerald restated a “buy” rating on shares of Eli Lilly And Co in a research report on Monday, February 4th. UBS Group dropped their price target on Eli Lilly And Co from $107.53 to $100.00 and set an “average” rating for the company in a research report on Friday, February 8th. Argus reiterated a “buy” rating on shares of Eli Lilly And Co in a research report on Thursday, December 27th. BMO Capital Markets lifted their price objective on Eli Lilly And Co from $124.00 to $132.00 and gave the stock an “outperform” rating in a research report on Monday, December 24th. They noted that the move was a valuation call. Finally, Bank of America set a $129.00 price objective on Eli Lilly And Co and gave the stock a “hold” rating in a research report on Thursday, March 21st. Ten analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $118.02.

Shares of NYSE LLY traded down $1.30 during midday trading on Friday, hitting $115.20. The stock had a trading volume of 9,805,773 shares, compared to its average volume of 6,415,027. The firm has a market capitalization of $119.33 billion, a P/E ratio of 20.76, a P/E/G ratio of 2.18 and a beta of 0.33. Eli Lilly And Co has a 1-year low of $77.09 and a 1-year high of $132.13. The company has a debt-to-equity ratio of 1.07, a current ratio of 1.73 and a quick ratio of 1.38.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Wednesday, February 6th. The company reported $1.33 earnings per share for the quarter, missing the consensus estimate of $1.36 by ($0.03). The firm had revenue of $6.44 billion during the quarter, compared to analyst estimates of $6.28 billion. Eli Lilly And Co had a net margin of 13.16% and a return on equity of 44.66%. The business’s revenue for the quarter was up 4.5% on a year-over-year basis. During the same period in the prior year, the firm earned $1.14 earnings per share. On average, equities research analysts expect that Eli Lilly And Co will post 5.66 EPS for the current fiscal year.

In related news, insider Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $127.01, for a total transaction of $127,010.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Alfonso G. Zulueta sold 4,000 shares of the business’s stock in a transaction that occurred on Thursday, January 31st. The stock was sold at an average price of $120.00, for a total value of $480,000.00. The disclosure for this sale can be found here. Insiders sold a total of 867,382 shares of company stock worth $109,265,182 over the last ninety days. Corporate insiders own 0.11% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Eli Lilly And Co (LLY) Shares Bought by River & Mercantile Asset Management LLP” was first published by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The correct version of this article can be read at https://www.baseballdailydigest.com/news/2019/04/21/eli-lilly-and-co-lly-shares-bought-by-river-mercantile-asset-management-llp.html.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: Understanding Price to Earnings Ratio (PE)

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.